Skip to main content

Table 4 GRADE score for outcomes

From: First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Outcomes

No of Participants (studies)

Follow up

Quality of the evidence (GRADE)

Relative effect (95% CI)

Anticipated absolute effects

Risk with Control

Risk difference with Objective Response Rate (95% CI)

Objective Response Rate

2143 (4 studies)

⊕ ⊕ ⊕⊝MODERATE

RR 1.11 (1.03 to 1.19)

Study population

534 ORR per 100

59 more per 1000 (from 16 more to 101 more)

Moderate

513 ORR per 1000

56 more per 1000 (from 15 more to 97 more)

Disease Control Rate

1006 (3 studies)

⊕ ⊕ ⊕⊝MODERATE

RR 0.95 (0.90 to 1.00)

Study population

872 DCR per 1000

44 fewer per 1000 (from 87 fewer to 0 more)

Moderate

868 DCR per 1000

43 fewer per 1000 (from 87 fewer to 0 more)

Complete response

1006 (3 studies)

⊕ ⊕ ⊕⊝MODERATE

RR 3.21 (1.27 to 8.12)

Study population

11 CR per 1000

24 more per 1000 (from 3 more to 77 more)

Moderate

14 CR per 1000

31 more per 1000 (from 4 more to 100 more)

Partial response

1006 (3 studies)

⊕ ⊕ ⊕⊝MODERATE

RR 1.10 (0.98 to 1.23)

Study population

505 PR per 1000

50 more per 1000 (from 10 fewer to 116 more)

Moderate

458 PR per 1000

46 more per 1000 (from 9 fewer to 105 more)

Stable disease

1006 (3 studies)

⊕ ⊕ ⊕⊝MODERATE

RR 0.66 (0.54 to 0.81)

Study population

357 per 1000

121 fewer per 1000 (from 68 fewer to 164 fewer)

Moderate

431 per 1000

147 fewer per 1000 (from 82 fewer to 198 fewer)

Progressive disease

1006 (3 studies)

⊕ ⊕ ⊕⊝MODERATE

   

RR 1.31 (0.84 to 2.05)

65 PD per 1000

20 more per 1000 (from 10 fewer to 68 more)

Moderate

69 PD per 1000

21 more per 1000 (from 11 fewer to 72 more)

Early objective response rate

330 (1 studie)

⊕ ⊕ ⊕⊝MODERATE1

RR 1.40 (1.16 to 1.68)

Study population

491 per 1000

197 more per 1000 (from 79 more to 334 more)

Moderate

491 per 1000

196 more per 1000 (from 79 more to 334 more)

Hematologic Adverse Events

1586 (3 studies)

⊕ ⊕ ⊕⊝MODERATE

RR 1.00 (0.86 to 1.16)

Study population

308HAE per 1000

0 fewer per 1000 (from 43 fewer to 49 more)

Moderate

326 HAE per 1000

0 fewer per 1000 (from 46 fewer to 52 more)

Nonhematologic Adverse Events

1586 (3 studies)

⊕ ⊕ ⊕⊝MODERATE

RR 1.24 (1.02 to 1.52)

Study population

175 NHAE per 1000

42 more per 1000 (from 3 more to 91 more)

Moderate

147 NHAE per 1000

35 more per 1000 (from 3 more to 76 more)

curative intent

1426 (2 studies)

⊕ ⊕ ⊕⊝MODERATE

RR 1.47 (1.55 to 1.88)

Study population

124 per 1000

59 more per 1000 (from 19 more to 110 more)

Moderate

117 per 1000

59 more per 1000 (from 19 more to 110 more)

Overall survival

2576 (5 studies)

⊕ ⊕ ⊕⊝MODERATE

HR 0.89 (0.81 to 0.98)

 

Progression free survival

2576 (5 studies)

⊕ ⊕ ⊕⊝MODERATE

HR 0.97 (0.90 to 1.05)

 
  1. *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio;
  2. GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect
  3. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
  4. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
  5. Very low quality: We are very uncertain about the estimate
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us